SOLARA Solara Active Pharma Sciences Q1 FY26 results (Apr–Jun 2025) and concall
Solara Active Pharma Sciences reported a strong Q1 FY26, with significant QoQ growth in revenue, EBITDA, and PAT, driven by a focus on high-margin business and cost containment. The company made substantial progress in debt reduction, lowering its net debt to EBITDA ratio. While the core API business showed resilience, the CRAMS division is in an investment phase, with expectations of a tepid year before becoming a meaningful contributor in 2-3 years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 300 | 273 | 319 |
| EBITDA | 58 | 45 | 57 |
| Net profit | 8 | -2 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
